ArticlePractical laboratory medicine2020
The challenge of producing an EQA for the COVID-19 pandemic.
Article in Practical laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ensuring diagnostic testing accuracy for patient care and public health- COVID-19 testing scale-up from an EQA provider's perspective.PLOS global public health · 2023Article
- Assessment of COVID-19 Molecular Testing Capacity in Jordan: A Cross-Sectional Study at the Country Level.Diagnostics (Basel, Switzerland) · 2022Article
- COVID-19 Serology Control Panel Using the Dried-Tube Specimen Method.The American journal of tropical medicine and hygiene · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has changed the clinical medicine landscape. The importance of pathology testing has come to the forefront. Patients or potential patients are dealing directly with laboratories as they line up in carparks or testing staff come to the front doors to obtain samples. Laboratories have had to increase capacity to deal with the high volumes of testing driven by the need to identify and quarantine cases. Supporting this effort, External Quality Assurance scheme providers have also needed to produce COVID-19 Proficiency Testing (PT) programs which are fit for purpose. COVID-19 Point of Care testing has become critical frontline testing and has required the PT programs to be simple to use, readily accessible and robust. We describe a COVID-19 PoCT Serology PT program supported by a mobile phone App. The App is described, and the advantages made explicit. This App suggests that the way that PoCT EQA/PT programs may be deployed in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.